Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by BioNTech SE

< Previous 1 2 Next >
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Planned Retirement of Sean Marett
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Inaugurate First African Site on December 18, 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.